Pharmaceuticals Japan

Japan KRAS Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $53.2 Mn Placeholder estimate
Estimate 2025 $72.2 Mn 6.6% of the global market
Projected 2034 $1.13 Bn 1,460.3% Adds $1.05 Bn over 9 forecast years
CAGR 2025–2034 35.7% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.6% of the global market.
  • In APAC, the largest is China at $93.6 Mn.
  • Fastest growing: India at 37.7% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.05 Bn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $53.2 Mn — —
2025 (base) $72.2 Mn +$19.0 Mn —
2026 (forecast) $98.0 Mn +$25.8 Mn +35.7%
2027 (forecast) $132.9 Mn +$35.0 Mn +84.1%
2028 (forecast) $180.4 Mn +$47.5 Mn +149.9%
2029 (forecast) $244.8 Mn +$64.4 Mn +239.1%
2030 (forecast) $332.2 Mn +$87.4 Mn +360.1%
2031 (forecast) $450.7 Mn +$118.6 Mn +524.4%
2032 (forecast) $611.7 Mn +$160.9 Mn +747.3%
2033 (forecast) $830.0 Mn +$218.4 Mn +1,049.8%
2034 (forecast) $1.13 Bn +$296.3 Mn +1,460.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan KRAS Inhibitors Market Analysis at a glance
Market size, 2025$72.2 Mn placeholder estimate
Forecast, 2034$1.13 Bn placeholder estimate
Growth (CAGR), 2025–203435.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAmgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials48 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

Bar chart: Japan KRAS Inhibitors market size, 2024–2034, placeholder estimates. $53.2 Mn in 2024, $72.2 Mn in 2025 and $1.13 Bn in 2034, 35.7% CAGR.
Japan KRAS Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in Japan

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in Japan

KRAS Inhibitors in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 48 studies on KRAS Inhibitors that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the KRAS Inhibitors market in Japan?
Placeholder estimate: about $72.2 Mn in 2025, rising to about $1.13 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the KRAS Inhibitors market in Japan growing?
Placeholder estimate: about 35.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the KRAS Inhibitors market report cover?
The report splits the market by target (KRAS G12C, KRAS G12D, Pan-KRAS), indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the KRAS Inhibitors market?
Key players include Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines and Novartis AG.
What is driving the KRAS Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates KRAS Inhibitors in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on KRAS Inhibitors are running in Japan?
48 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on KRAS Inhibitors?
PubMed lists 440 papers on KRAS Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on oncology

See the topic